Send to a Friend Font Size: Increase Decrease

HNSA and 24H Related Headlines

Sep 24, 2025 02:07PM Hansa Biopharma's imlifidase meets primary endpoint in Phase 3 kidney trial
Sep 24, 2025 02:06PM Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation

HNSA and 24H Related Press Releases

Sep 24, 2025 02:06PM Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation

HNSA and 24H Related SEC Filings